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Accepted 6 May 2009Mesenchymal stem cell preparations have been proposed for muscle regeneration in
musculoskeletal disorders. Although MSCs have great in vitro expansion potential and possess
the ability to differentiate into several mesenchymal lineages, myogenesis has proven to be much
more difficult to induce. We have recently demonstrated that Pax3, the master regulator of the
embryonic myogenic program, enables the in vitro differentiation of a murine mesenchymal stem
cell line (MSCB9-Pax3) into myogenic progenitors. Here we show that injection of these cells into
cardiotoxin-injured muscles of immunodeficient mice leads to the development of muscle tumors,
resembling rhabdomyosarcomas. We then extended these studies to primary human
mesenchymal stem cells (hMSCs) isolated from bone marrow. Upon genetic modification with a
lentiviral vector encoding PAX3, hMSCs activated the myogenic program as demonstrated by
expression of myogenic regulatory factors. Upon transplantation, the PAX3-modified MSCs did not
generate rhabdomyosarcomas but rather, resulted in donor-derived myofibers. These were found
at higher frequency in PAX3-transduced hMSCs than in mock-transduced MSCs. Nonetheless,
neither engraftment of PAX3-modified or unmodified MSCs resulted in improved contractility.
Thus these findings suggest that limitations remain to be overcome beforeMSC preparations result
in effective treatment for muscular dystrophies.
© 2009 Elsevier Inc. All rights reserved.Keywords:
Mesenchymal stem cells
Pax3
Muscle differentiation
Dystrophin
Transplantation
TumorsIntroduction
Muscular dystrophies are genetically and clinically heterogeneous
disorders characterized by progressiveweakness and degeneration
of the skeletal muscles that control movement. Among these
disorders, Duchenne muscular dystrophy (DMD) is the most
common, affecting 1 out of every 3500 live born boys. DMD is an
X-linked recessive muscle disorder caused by mutations in thete, University of Minnesota
erlingeiro).
r Inc. All rights reserved.
ngraftment of mesenchym
), doi:10.1016/j.yexcr.200dystrophin gene, resulting in the absence of dystrophin in skeletal
muscle and other tissues [1–3]. Current treatment involves
pharmacological control of inflammation which ameliorates
symptoms but does not cure or extend the life expectancy of
affected patients.
Bone marrow transplantation is at the vanguard of cellular
therapies and it has beenwidely and successfully used in clinics for
the treatment of congenital, malignant, and degenerative diseases, 4-124 Nils Hasselmo Hall, 312 Church St. S.E., Minneapolis 55455,
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controversial studies has exploited the plasticity of bone marrow
cells and their therapeutic potential on non-hematological dis-
orders [4–9], including muscular dystrophies [10–15]. Ferrari et al.
were the first to document that BM cells had the ability to migrate
from the circulation into cardiotoxin-injured muscles, and partici-
pate in skeletal muscle regeneration. These results were further
confirmed by several investigators that applied BM transplantation
tomdxmice, an animal model for DMD [11–13]. Despite the initial
enthusiasm, quantification of engraftment revealed that the
number of donor-derived myofibers in transplanted mice was
rather low (<1%) [11,16], leading to questioning of the biological
and therapeutic relevance of these findings. As observedwith other
cell lineages, it is possible that the low level engraftment observed
inmuscle tissues results solely fromcell fusion rather than fromBM
plasticity [17–22]. It is also plausible to assume that a cell
population with limited myogenic potential was transplanted in
these experiments, given that most reports described above made
use of whole BM, which is highly heterogeneous.
BM is well-known as a source of hematopoietic stem cells, but it
also contains a stromal cell population, known as mesenchymal
stem cells or marrow stromal cells (MSCs), that is endowed with
the ability to self-renew and differentiate into multiple mesench-
ymal lineages, including bone, fat, cartilage, and connective tissue
[23–25]. Experimental approaches involving induction of MSCs
with 5-azacytidine [26], co-culture of MSCs with myoblasts [27] or
myoblast-conditioned medium [28], and more recently activated
Notch [29], suggest that skeletal muscle progenitors can also be
obtained from MSCs. Although MSCs represent less than 0.01% of
the BMmononuclear cell fraction, they are easily expanded in vitro
and thus, amenable to genetic manipulation. We have recently
demonstrated that by overexpressing Pax3, the master regulator of
the myogenic program, a mesenchymal stem cell line can be
specifically reprogrammed to differentiate into the myogenic
lineage [30]. These results led us to test their myogenic potential
in vivo as well as to investigate whether PAX3 is able to reprogram
primary human MSCs, and whether resulting reprogrammed cells
are capable of promoting muscle regeneration in vivo.Materials and methods
MSC isolation and culture
Human BM samples were purchased from Cambrex. hMSCs were
isolatedaccording to previously describedprotocol [25]. Briefly, cellsTable 1 – Specific human sense and anti-sense primers for quanti
Gene Primer sense sequence
hMYOD CACTCCGGTCCCAAATGTAG
hMYF5 GATTCACAGCCTCGAACTCC
hMYOGENIN TAGCAGGGGCCTCCTAAGC
hMHC ATGGCAGGTCTGGATGAAAC
hGAPDH CATCTTCCAGGAGCGAGAT
MHC, myosin heavy chain type IIb.
Please cite this article as: E.J. Gang, et al., Engraftment of mesenchym
by functional recovery, Exp. Cell Res. (2009), doi:10.1016/j.yexcr.200were separated from 10 to 20 ml of marrow diluted with four
volumes of Minimum Essential Medium Alpha Medium (α-MEM,
Invitrogen) containing 10% FBS (Atlanta Biologicals) by centrifuga-
tion at 900 g for 15 min. Cells were washed with cold Dulbecco's
phosphate-buffered saline (DPBS) once and plated at 2×106 cells
per cm2 inMSCexpansionmediumconsistingof low-glucoseDMEM
supplemented with 40% MCDB-201 (Invitrogen), 10% FBS, 1×insu-
lin–transferrin–selenium (ITS; Sigma), 1×linoleic-acid–bovine-
serum-albumin (Sigma), 10−8 M dexamethasone (Sigma), 10−4 M
ascorbic acid 2-phosphate (Sigma), 50 U/ml penicillin/streptomy-
cin (Invitrogen), 10 ng/ml of hPDGF-BB (Peprotech), and 10 ng/ml
of hEGF (Peprotech). After 72 h of culture, suspended cells were
removed and replaced with fresh media. Medium was changed
every 3 days thereafter. hMSCs grew as colonies which were
detached with 0.1% trypsin–EDTA and sub-cultured at a density of
4–8×103 cells per cm2.
Lentiviral infection and purification of GFP+ mesenchymal
stem cells
The multiple cloning site (BglII–EcoRI–NotI–SalI) of pBS was PCR-
amplified and cloned into pGEM-T (Promega) to generate pGEM-
BS. pGEMiresGFP was generated by inserting 1.3 kb SalI-digested
iresGFP fragment from pMSCViresGFP [31] into the SalI site of
pGEM-BS. The lentiviral vector pSAMwas generated by inserting a
1.3 kb BglII/NdeI-digested and filled-in iresGFP fragment from
pGEMiresGFP into the BamHI/EcoRI-digested and filled-in cloning
site of FUGW [32].We refer to this vector as pSAM. Lentiviral vector
pSAM-Pax3 was created by sub-cloning the cDNA for Pax3
obtained from pSPORT-Pax3 (BC048699, Open Biosystems) into
pSAM as an EcoR I/BamH I digested and BamH I filled-in fragment.
This vector was co-transfected with packaging and coat protein
constructs Δ8.91 and pVSVG, respectively, into 293T cells using the
FuGENE 6 transfection reagent (Roche) as recommended by the
manufacturer. Virus-containing supernatant was collected 48 h
after transfection and filtered through a 0.45 μm filter before use.
MSC cells were suspended in 3 ml of viral supernatant containing
10 ng/ml hPDGF-BB, 10 ng/ml hEGF, and 8 μg/ml polybrene
(Sigma). Cells were then transferred to 6-well plates and
centrifuged at 2500 rpm for 90 min at 33 °C on a Hettich
centrifuge. After a 4 h-incubation at 37 °C with 5% CO2 in air,
supernatant was removed and changed with fresh MSC expansion
medium as described above. Two days following infection, cells
were harvested and sorted based on the gating of GFP+ on the FITC
channel. GFP+ hMSCs weremaintained in MSC expansionmedium
for further in vitro and in vivo studies.tative real-time PCR analysis.
Primer anti-sense sequence Product size (bp)
TTCCCTGTAGCACCACACAC 180
TGAAGCCTTCTTCGTCCTGT 125
CTCTGGTCCCCTGCTTTACC 193
CCAAGGACCCTTCAAGATCA 172
TGCAAATGAGCCCCAGCCTT 114
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Fig. 1 – Development of rhabdomyosarcoma following the transplantation of MSCB9-Pax3 cells. (A) MSCB9-Pax3 or MSCB9-Vector
(MSCB9-Vec) cells were injected into cardiotoxin-injured TAmuscles of Rag2−/− γc−/−mice. Contralateral TA muscles were used as
controls. Engrafted cells (LacZ+) were detected at 4-week (i. upper two panels) and 8-week post-transplantation (i. lower two
panels) by X-gal staining. These latter samples were also examined by H&E staining (ii. lower panel). (B) Immunofluorescent
staining ofmuscle cryosections at 4 weeks post-transplantation forMyoD andMyogenin (stainingwith Cy3 in red); direct GFP signal
(green); merge for GFP and MyoD or Myogenin (cells expressing both are seen in yellow/orange); DAPI staining in blue, and merge
for DAPI and MyoD or Myogenin (cells expressing both are seen in purple). Pictures were taken at 200× (A.i and B) and 600× (A.ii).
Scale bar is 100 μm.
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Western blots were performed using the following antibodies:
mouse monoclonal anti-Pax3 (R and D Systems), and mouse
monoclonal anti-actin (Sigma).
FACS analysis of GFP+ cells
Pax3- or Vector control-transduced MSCs at passage 2 were
trypsinized with 0.1% Trypsin–EDTA and washed with blocking
buffer (DPBS with 2% FBS), suspended in the same buffer
containing 0.25 μg/106 cells of Fc block (Pharmingen) and placed
on ice for 5 min. Allophycocyanin (APC)- or Phycoerythrin (PE)-
conjugated mouse antibodies to human markers including CD73,
CD44, CD90, CD45, CD34 (Pharmingen), CD105 (Serotec), andFig. 2 – Activation of the myogenic program in PAX3-expressing hM
sorted cells in hMSCs transduced with PAX3 or vector control. GFP i
were sorted according to represented gates and cultured in MSC ex
100 μm. (B) Immunofluorescence for PAX3 (Cy3, red) in hMSC-PAX
taken at 400×. Scale bar is 100 μm. (C) Western blot analysis for PA
analysis by real-time PCR for myogenic-specific markers in hMSC-P
GAPDH (y axis). Error bars indicate standard errors from 3 indepen
Please cite this article as: E.J. Gang, et al., Engraftment of mesenchym
by functional recovery, Exp. Cell Res. (2009), doi:10.1016/j.yexcr.200CD56 (NCAM; BioLegend) were added at 1 μg/106 cells and
incubated at 4 °C for 20 min before washing with blocking buffer.
As matching isotype controls, APC- or PE-conjugated mouse anti-
IgG antibodies (Pharmingen) were used. Cells were then analyzed
on FACS Aria (Becton-Dickinson) after addition of propidium
iodide (Pharmingen) to exclude dead cells.
Myogenic induction
For myogenic differentiation, cells were cultured for up to 3 weeks
in several muscle inductive conditions as follows: LG-DMEM
supplemented with 10% FBS, bFGF (10 ng/ml; Peprotech),
neuregulin (200 ng/ml; Peprotech), hPDGF-AA (5 ng/ml; Pepro-
tech), and forskolin (FSK, 5 μM; Calbiochem); LG-DMEM supple-
mented with 2% horse serum (HS, Atlanta Biologicals) and 1×ITS,SCs. (A) FACS profile for GFP expression and morphology of
s indicated on x axis, and autofluorescence on y axis. GFP+ cells
pansion medium. Pictures were taken at 200×. Scale bar is
3 and hMSC-Vector cells. DAPI staining in blue. Pictures were
X3 in hMSC-PAX3 and hMSC-Vector cells. (D) Gene expression
AX3 and hMSC-Vector cells. Transcripts were normalized to
dent experiments.
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(5 μM; Sigma); as controls, we also evaluated cells that were
maintained in MSC expansion medium (with and without growth
factors) and α-MEM supplemented with 16.5% FBS.
RNA isolation and real-time quantitative PCR analysis
Total RNAwas isolated using Trizol (Invitrogen) as recommended by
themanufacturer. First strand cDNAwas produced using SuperscriptFig. 3 – Characterization of hMSCs-PAX3. Flow cytometric analyses
isotype or secondary control staining profile (thin line) versus spec
the fraction of cells that express a given surface antigen. This analy
Please cite this article as: E.J. Gang, et al., Engraftment of mesenchym
by functional recovery, Exp. Cell Res. (2009), doi:10.1016/j.yexcr.200II reverse transcriptase (Invitrogen) with Oligo dT. For gene expres-
sion assays, 2 μl of cDNA from reverse-transcription of total RNA as a
template was amplified using SYBR Green Master Mix reagent
(Applied Biosystems) and 7500 Real-Time PCR System (Applied
Biosystem). The muscle-specific primers for human MYOD, MYF5,
MYOGENIN, MHC, GAPDH and PCR product sizes are described in
Table 1. For PAX3, a probe setwas acquired fromApplied Biosystems.
The data are reported as a ratio of absolute mRNA copy number of
each specific gene to the absolute copy number of GAPDH.of hMSC-PAX3 and hMSC-Vector cells at passage 2. Plots show
ific antibody staining profile (thick line). Percentages represent
sis was performed twice.
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Animal experiments were carried out according to protocols
approved by the UT Southwestern Medical Center Institutional
Animal Care and Use Committee and met US National Institutes of
Health guidelines for the humane care of animals. Six- to eight-
week-old Rag2−/− γc−/− immunodeficient mice (Taconic labora-
tories) and C57 BL/10ScSN-Dmdmdx/j (X-linked muscular dystro-
phy; Jackson Laboratory) were used as recipients for the
transplantation study. One day before transplantation, 75 μl of
cardiotoxin (10 μM, Sigma) was injected into both tibialis anterior
(TA)muscles of eachmouse to inducemuscle injury. 24h later, Pax3-
or Vector-transducedMSCB9 or primary humanmesenchymal stem
cells were injected (1×106 in 50 μl of phosphate-buffered saline)
into the right TAmuscles of each group. As control, 50 μl of PBSwere
injected in the left TA muscle of animals. For immuno-suppression,
mdx mice received a daily dose of 5 mg/kg FK 506 (Tacrolimus;
Sigma) intra-peritoneally (IP) from the day before cell injection until
the time of euthanasia (4 weeks after transplantation).Fig. 4 – Effects of several induction protocols on the myogenic diff
hMSC-PAX3 and hMSC-Vector cells after 4 weeks under several myo
expression profile by real-time PCR analysis. Transcripts were norm
from 4 independent experiments. (C) Immunofluorescent staining
cells grown under expansion (#1) or myogenic induction (#2, bFGF
Arrows indicate nuclei within the myotube. All photographs were ta
MHC+ in these hMSC-PAX3 cultures. Error bars indicate standard e
Please cite this article as: E.J. Gang, et al., Engraftment of mesenchym
by functional recovery, Exp. Cell Res. (2009), doi:10.1016/j.yexcr.200Immunofluorescent staining of cultured cells and tissue
sections
TA muscles were isolated, embedded in OCT compound (Tissue-
Tek) and immediately frozen in isopentane cooled in liquid
nitrogen. Serial cryostat sections (8–12 μm) were collected. For
immunofluorescence staining, cells cultured on slides and tissue
cryosections were fixed using 4% paraformaldehyde/PBS (acetone
was applied for dystrophin staining), permeabilized with 0.5%
Triton X-100 (Sigma), and blocked with 10% goat serum (or 3%
BSA), and then incubated with primary antibodies including GFP
(Molecular Probes), Pax3 (R and D Systems), MyoD (both from BD
Biosciences), MHC (Developmental Studies Hybridoma Bank), and
dystrophin (Abcam). Cy2 and Cy3 (Jackson Immunoresearch
Laboratories) secondary antibodies were used. DAPI (4,6-diami-
dino-2-phenylindole; Fluka) was used to counter-stain nuclei.
Nonspecific isotype control antibodies were used as negative
controls. X-gal staining was performed for detection of LacZ+ cells.
Sections were fixed with 0.2% glutaraldehyde in washing buffererentiation of hMSCs. (A) Representative morphologies of
genic induction protocols and, (B) their respective gene
alized to GAPDH (y axis). Error bars indicate standard errors
for MYOD and MHC (Cy3, red) in hMSC-PAX3 and hMSC-Vector
and neuregulin) medium. Cells are co-stained with DAPI (blue).
ken at 200×. Scale bar is 100 μm. (D) Percentage of MYOD+ and
rrors from 2 independent experiments.
al stem cells into dystrophin-deficient mice is not accompanied
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ARTICLE IN PRESS(5mMEGTA, 2mMMgCl2, 0.1 M sodium phosphate buffer, pH 7.3),
rinsed with washing buffer and incubated overnight at 37 °C
in X-gal solution (2 mM 5-bromo-4-chloro-3-indolyl-b-D-galacto-
pyranoside/dimethyl-formamide, 4 mM K3Fe(CN)6, 4 mM K4Fe
(CN)6U3H2O and 1 mM MgCl2 in washing buffer. Sections were
then counterstained with Hematoxylin and Eosin (H&E) staining,
as described [33].Please cite this article as: E.J. Gang, et al., Engraftment of mesenchym
by functional recovery, Exp. Cell Res. (2009), doi:10.1016/j.yexcr.200Muscle preparation for mechanical studies
For the measurement of contractile properties, the mice were
anaesthetizedwith sodiumpentobarbitone (70mg/kg I.P.) and intact
tibialis anterior (TA) muscles were dissected and placed in an
experimental organ bath filled with mammalian Ringer solution
containing (mM):NaCl 120.5;NaHCO3 20.4; glucose 10;KCl 4.8; CaCl2al stem cells into dystrophin-deficient mice is not accompanied
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ARTICLE IN PRESS1.6; MgSO4 1.2; NaH2PO4 1.2; pyruvate 1.0, adjusted to pH 7.4. The
chamber was perfused continuously with 95% O2–5% CO2 and
maintained at a temperature of 25 °C. The muscles were stimulated
byanelectric fieldgeneratedbetween twoplatinumelectrodesplaced
longitudinally on either side of the muscle (square wave pulses 25 V,
0.2 ms in duration, 150 Hz). Muscles were adjusted to the optimum
length (Lo) for the development of isometric twitch force and a 5min
recovery period was allowed between stimulations. Optimal muscle
length (Lo) and stimulation voltage (25 V) were determined from
micromanipulation of muscle length and a series of twitch contrac-
tions that produced maximum isometric twitch force. In brief, after
determination of optimal muscle length (Lo) and measurement of
maximum isometric tetanic force, total muscle fiber cross-sectional
area (CSA)was calculated bydividingmusclemass (milligram)by the
product of fiber length (millimeter) and 1.06mg/mm3, the density of
mammalian skeletal muscle. Specific force (sF0) was determined by
normalizing maximum isometric tetanic force to CSA.
Statistical analysis
Differences between samples were assessed by using the Student's
two-tailed t test for independent samples.Fig. 5 – Engraftment of hMSCs is improved in the presence of
PAX3. Human mesenchymal stem cell preparations transduced
with PAX3 or Vector only were transplanted into tibialis
anterior (TA) muscles frommdxmice that had been previously
injured with cardiotoxin. (A) Dystrophin expression (in red) in
wild-type mice (top row) and untreated mdx mice (second
row). Third and fourth rows represent detection of dystrophin+
muscle fibers in mdx mice 4 weeks after transplantation with
hMSC-PAX3 and hMSC-Vector cells, respectively. Scale bar is
100 μm. (B) Percentage of Dystrophin+ myofibers per field in
transplanted muscles. For each group, 80 high power fields
(200×) were selected and photographed at random areas, and
myofiber number was recorded. The number in the parenthesis
indicates the number of mice per group. ⁎P< 0.01.Results
Rhabdomyosarcomas upon transplantation of MSCB9-Pax3
cells
We have previously shown that Pax3 enables the commitment of a
murinemesenchymal stem cell line toward themyogenic lineage in
vitro [30]. We transplanted these cells into cardiotoxin-injured
muscles of immunodeficient mice, and observed tumors arise by
4 weeks post-transplantation. These tumors were of donor origin,
as evidenced by LacZ staining and GFP fluorescence (Figs. 1A, B).
H&E staining of these cryosections revealed cell death (necrosis) in
abundance as well as a large number of small rounded cells
characterized by large nuclei and little cytoplasm (Fig. 1A.ii, lower
left panel). Pathological analyses of these samples classified these
tumors as rhabdomyosarcomas. Indeed these very poorly differ-
entiated neoplasms were positive for MyoD and Myogenin
(Fig. 1B), a profile also characteristic of rhabdomyosarcoma
[34–36]. Rhabdomyosarcomas (RMS) represent the most common
soft tissue tumors affecting children and young adolescents, and
can be sub-divided in twomain categories, embryonal and alveolar.
The latter is generallymore aggressive and can be identified inmost
instances by the presence of the fusion oncogene Pax3/Forkhead or
Pax7/Forkehead resulting from reciprocal chromosomal transloca-
tions [37,38]. Although we did not observe the development of
tumors inmice injectedwithMSCB9-Vector control cells at 4weeks
(Fig. 1A.i) or at 8 weeks (Supplementary Fig. 1) after the
transplantation, these cells were found at increasing levels as
mononuclear cells in recipient muscles over time (Supplementary
Fig. 1), suggesting they may eventually develop a tumor.
PAX3 promotes the activation of the myogenic program in
primary hMSCs
To assess whether the generation of rhabdomyosarcoma in vivo
was due specifically to Pax3 or a combinatory effect of Pax3 withPlease cite this article as: E.J. Gang, et al., Engraftment of mesenchym
by functional recovery, Exp. Cell Res. (2009), doi:10.1016/j.yexcr.200the use of MSCB9, an immortalized cell line [39], we investigated
next the ability of Pax3 to reprogram primary mesenchymal stem
cells into myogenic progenitors, and whether these cells in vivo
would develop rhabdomyosarcoma or produce muscle engraft-
ment. For this purpose, we transduced Pax3 into primary mouse
MSC preparations. Although these cells were amenable toal stem cells into dystrophin-deficient mice is not accompanied
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(data not shown), after isolation, transduction, and sorting, cells
were left with limited proliferative potential, with or without
Pax3. This was probably due to the fact that cells were approaching
senescence.
Based on these results, we decided to transduce primary
human MSC preparations, which are known to grow much better
than their mouse counterparts. Experiments were conducted with
MSC preparations obtained from two independent human BM
samples. Two days following lentiviral infection, both hMSC-PAX3
and control vector-transduced hMSC were FACS sorted for GFP+
cells (Fig. 2A, upper panel). In the presence of MSC expansion
medium, both sorted cell fractions, hMSC-PAX3 and hMSC-Vector,
proliferated at a similar rate and presented no apparent morpho-
logical differences (Fig. 2A, lower panel). Expression of PAX3 by
hMSC-PAX3 but not hMSC-Vector cells was confirmed by immu-
nofluorescent staining and Western blot analysis (Figs. 2B, C).
Gene expression analyses for myogenic regulatory factors (MRFs)
demonstrated up-regulation of MYOD in hMSC-PAX3 cultures
(Fig. 2D). MYF5 and MYOGENIN, as well as MYOSIN HEAVY CHAIN
(MHC), a marker of terminal muscle differentiation, were barely
detectable (Fig. 2D) under these expansion culture conditions.
Both PAX3-transduced and control MSC preparations were
negative for CD45 and CD34, while maintaining high expression
levels of CD73, CD90, CD105, and CD44, a profile characteristic of
MSCs (Fig. 3). The only antigen found to be expressed differentially
in hMSC-PAX3 was CD56, a known marker for myogenic
progenitors. While undetectable in hMSC-Vector cells, CD56 was
up-regulated in PAX3-transduced MSCs (23.6%; Fig. 3).
To test their muscle differentiation potential in vitro, we
cultured hMSC-PAX3 and hMSC-Vector cells under several muscle
inductive conditions (#2, 10% FBS, bFGF, neuregulin, PDGF-AA andFig. 6 –MSCs fail to promote in vivo functional recovery. Values show
mice per group±SEM. (A) Representative example of force tracing
transplanted mdx mice. Blue and red lines show force tracing from
(control), respectively. Muscles at L0were stimulated for 2 s with a 1
recorded. (B) Effect of cell transplantation on specific force (sF0:F0 n
(E) Number of myofibers per field in analyzed muscles. For each gr
photographed and myofiber number was recorded in a blinded fas
Please cite this article as: E.J. Gang, et al., Engraftment of mesenchym
by functional recovery, Exp. Cell Res. (2009), doi:10.1016/j.yexcr.200forskolin) [29]; #3, 2% HS [40], and #4, 10% FBS and 5-azacitidine
for up to 4 weeks [26] (Fig. 4), along with control conditions,
including basic MSC medium (#1, 16.5% FBS) [39], complete
expansion medium (#5, 10% FBS and PDGF-BB/EGF) [39], and
expansion medium without growth factors (#6). This latter
condition was investigated to assess whether growth factor
withdrawal would allow the differentiation of hMSC-PAX3 and
hMSC-Vector cells into myogenic cells. From all these conditions,
myogenic differentiation was more prominent with medium
containing bFGF, neuregulin, PDGF-AA and forskolin, and the
induction medium containing 2% HS (conditions 2 and 3,
respectively), as evidenced by gene expression analysis which
revealed up-regulation ofMYOD,MYF5,MYOGENIN, and to a lesser
extent, MHC (Fig. 4B). Irrespective of the induction culture
conditions, myogenic regulatory factors were scarcely detectable
in hMSCs-Vector control cells. These results were corroborated by
immunofluorescent staining for MYOD and MHC comparing
hMSC-PAX3 to hMSCs-Vector cells (Fig. 4C), in the presence of
proliferation (16.5% FBS, #1) and induction medium containing
bFGF, neuregulin, PDGF-AA, and forskolin (#2). The inductive
differentiation condition (#2) resulted in the generation ofMYOD+
and MHC+ cells (23.84%±3.22% and 4.5%%±1.7%, respectively),
with a fusion index of 3.1%±1.8%.
PAX3-modified primary human MSCs do not generate
rhabdomyosarcomas in vivo
To test the myogenic differentiation potential of hMSC-PAX3 cells
in vivo, we initially transplanted these cells as well as hMSC-Vector
control cells into the TA muscles of CTX-injured Rag2−/− γc−/−
immunodeficient mice. At 8 weeks post-transplantation rather
than rhabdomyosarcoma, as previously observed with MSCB9-n are the results of 3 independent experiments on a total of 14
in TA muscles from hMSC-Vector- (left) and hMSC-PAX3- (right)
muscles that had received cell transplantation or PBS
50 Hz, 25 V, 0.2 ms square pulse and isometric tetanic force was
ormalized to CSA). (C, D) Average weight and CSA, respectively.
oup, 10 high power fields (100×) selected at random were
hion by 2 independent investigators.
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(data not shown). The fact that PAX3-transduced primary human
MSCs did not result in rhabdomyosarcoma formation in vivo
suggests that Pax3 per se does not lead tomuscle tumor, onlywhen
used in combination with an immortalized cell line.
To evaluate whether these cells have the ability to restore
dystrophin expression in mdx mice, we injected either PAX3-
transduced or Vector control MSCs into CTX-injured TA muscles.
As an internal control, contralateral TA muscle was injected with
the same volume (50 μl) of PBS. Four weeks later, dystrophin
expressionwas observed in both groups receiving cell transplanta-
tion, although more clusters of dystrophin+ myofibers were
detected in hMSC-PAX3 than their vector control group (11% versus
7%; Figs. 5A, B).
Restored dystrophin expression is not accompanied by
functional recovery
Finally, to assess whether cell engraftment would result in an
improvement in muscle function, we measured the contractile
properties of TA muscles from mdx mice following the transplan-
tation of hMSC-PAX3 or hMSC-Vector cultures. Both groups
showed similar isometric tetanic force (Fig. 6A) and specific
force (Fig. 6B) when compared to their control counterparts.
Accordingly, therewere no changes inmuscleweight (Fig. 6C), CSA
(Fig. 6D), or numbers of myofibers between PBS- and cell-
transplanted muscles (Fig. 6E). These results suggest that engraft-
ment by MSCs is not sufficient to trigger functional improvement
of dystrophic muscles.Discussion
A growing body of evidence suggests that cell-based therapies
might be beneficial for the treatment of neuromuscular conditions.
Encouraging results have been obtained following the transplanta-
tion of several stem cell preparations [29,41–48] into mouse
models of muscular dystrophy. Although most of these studies
comprise cell populations isolated directly from muscle tissues,
such as satellite cells andmesoangioblasts, stromal cells from bone
marrow [29] and adipose tissues [46,47] have also been attributed
with in vivo muscle regenerative potential.
In terms of cells isolated from bone marrow, in vivo skeletal
muscle regeneration has been observed with human MSCs
genetically manipulated with activated Notch [29]. Engraftment
of these human cells was observed following their intramuscular
or intravenous injection into immunosuppressed rats as well as
into immunodeficient dystrophic (mdx-nude) mice previously
injured with cardiotoxin (CTX) [29]. The ratio of donor-derived
myofibers (GFP+) in engrafted muscles varied between 14.7% and
50.9%. Although muscle function was not investigated, with such
levels of chimerism, one would expect improvement in muscle
function following the transplantation of these cells. The mechan-
ism bywhich activated Notch acts in this study is unclear since this
gene is well recognized for its repressive effect on myogenic
determination [49–52].
Wehavedemonstrated thatPax3, anessential transcription factor
for embryonic muscle specification [53–56], enables the generation
of early skeletal muscle progenitors from differentiating mouse
embryonic stem cells [57]. Upon local and systemic transplantationPlease cite this article as: E.J. Gang, et al., Engraftment of mesenchym
by functional recovery, Exp. Cell Res. (2009), doi:10.1016/j.yexcr.200into mdxmice, these cells produce substantial engraftment of adult
myofibers, which are endowed with superior contractile function
[57]. In order to assess whether Pax3 would enable the reprogram-
ming of adult cells towards the myogenic lineage, we began by
extending this approach to a mesenchymal stem cell line (MSCB9)
derived from adult mouse bone marrow [39]. As recently reported,
Pax3 allowed the activation of the myogenic program in these cells,
which occurred at the expense of their differentiation into fat, bone,
and cartilage tissues [30]. This effect appears cell type-selective
since overexpression of Pax3 in endothelial cells failed to promote
the activation of the myogenic program [30].
Here we show that transplantation of Pax3-transduced MSCB9
cell preparations into CTX-injured skeletal muscles of immunode-
ficient mice leads to the development of muscle tumors,
resembling rhabdomyosarcomas [34–36]. Most alveolar rhabdo-
myosarcomas (ARMS) are characterized by the presence of a
translocation-mediated fusion of Pax3 or Pax7 to a Fkhr gene, t
(2;13) and t(1;13), respectively. Pax3/Fkhr fusion gene is more
common, being detected in 55%–75% of ARMS cases [37,38,58,59].
Nevertheless, both Pax3/Fkhr and Pax7/Fkhr fusion proteins are
strong transcriptional activators and are thought to play a crucial
role in the origin of ARMS by interfering with the muscle
development program. Since transplantation of Pax3-transduced
primary MSCs did not generate tumors, our studies demonstrate
that ARMS-like tumors were not solely due to Pax3 but a
combination of Pax3 and mutations acquired by MSCB9, an
immortalized cell line with karyotypic abnormalities [39]. Inter-
estingly, successful generation of a mouse model for ARMS was
obtained only when combining conditional expression of Pax3/
Fkhr with Ink4a/ARF and Trp53 loss of function [36]. Previous
transgenic mice expressing only Pax3/Fkhr showed aberrant
myogenesis but no tumor formation [60,61]. Additional mutations
probably play a role in ARMS by providing a growth advantage to
affected cells.
Our in vitro data with primary human MSCs show that PAX3
indeed has the ability to activate the myogenic program in MSCs,
although to a lesser extent than observed with the MSCB9 cell line
[30]. Importantly, transplantation of PAX3-transduced primary
human MSC preparations produces muscle engraftment, rather
than muscle tumors. However engraftment into mdx mice is not
accompanied by functional recovery, as evidenced by measuring
the contractility force of engrafted muscles. It is possible that the
levels of engraftment obtained here (10.8+3.6%) are not enough
to trigger functional improvement. As discussed above, high levels
of engraftment have been obtained following the transplantation
of human MSCs transduced with activated Notch into CTX-injured
immunosuppressed rats and mdx-nude mice [29] but to date,
functional measurements have not been documented. It may also
be the case that human-derived myofibers have impaired function
in the mouse environment. Nonetheless, reports of improvement
in muscle function following the transplantation of specific human
cell populations have been described using the scid/mdx mouse
model [48,62].
A recent study by Rose et al. has shown that although bone
marrow-derived MSCs can be induced to adopt a cardiac muscle
phenotype, by expressing cardiac-specific makers, they still retain
the MSC phenotype and fail to become functional cardiomyocytes
in vitro [63]. The samemay be the case here since PAX3-transduced
hMSCs still maintain a MSC phenotype (Fig. 3), despite expression
of MYOD and CD56. These results suggest that the presence ofal stem cells into dystrophin-deficient mice is not accompanied
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ARTICLE IN PRESSDystrophin+ myofibers in transplanted mice may result exclu-
sively from fusion of donor cells with resident myofibers rather
than from the reprogramming of MSCs into myogenic progenitors.
This hypothesis is reinforced by the lack of evidence that hMSC-
Pax3 cells contribute to the satellite cell compartment in vivo
(persona). If this is the case, it is possible that multiple cell
injections might be necessary in order to trigger functional
improvement of dystrophic muscles by MSC therapy. Thus further
development is necessary in order to overcome the limitations
associated with the therapeutic application of MSC preparations
for muscular dystrophies.Acknowledgments
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